LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs
NEW YORK, December 29, 2025, 17:45 ET — After-hours Shares of Eli Lilly and Company (LLY) were up…
China’s new commercial insurance model could broaden access to Alzheimer’s drugs
ChiÂna’s new comÂmerÂcial inÂsurÂance forÂmuÂlaÂry looks to exÂpand paÂtient acÂcess to Alzheimer’s disÂease medÂiÂcines from Eli LilÂly and…
Novo’s Wegovy pill to test demand from consumers with cash
LONDON, Dec 23 (Reuters) – Novo Nordisk’s newly approved weight-loss pill version of Wegovy will be a test…
Eli Lilly’s pill solves the biggest problem with weight loss
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly…
Eli Lilly Scores Another Major Win: Time to Buy?
Eli Lilly’s next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should…
Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here,…
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
By Deena Beasley Dec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their…
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump
24/7 Wall St. Abbott Laboratories (ABT) grew revenue 6.9% with medical devices up 14.8% to $5.45B. Abbott reaffirmed…
1 Major Factor Behind the Healthcare Sector’s Recent Surge
Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…
Time to Buy the Dip?
Eli Lilly’s decision to reduce the price of its popular weight loss drug makes more sense than it…
Is Eli Lilly a Millionaire Maker?
Eli Lilly just agreed to lower the price of its blockbuster GLP-1 weight loss drug. More than half…